Kura Oncology, Inc. (KURA) shareholders
Close on Nov 18, 2026Market cap $652.97MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (9.99%), Lampert Mark N (9.99%) and 3 more | 8,677,018 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Aaron Cowen Joint filing with Montanova Capital, LLC (9.70%), Averill Master Fund, Ltd. (8.80%) | 8,575,422 | 9.70% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 7,908,832 | 8.90% | 13G (passive) amendment | Sep 30, 2026 |
| Suvretta Capital Management, LLC Joint filing with Aaron Cowen (6.70%), Averill Master Fund, Ltd. (5.90%) | 5,198,189 | 6.70% | 13G (passive) amendment | Dec 31, 2024 |
| Armistice Capital, LLC Joint filing with Steven Boyd (5.67%) | 4,936,000 | 5.67% | 13G (passive) amendment | Dec 31, 2025 |
| State Street Corporation | 4,931,090 | 5.70% | 13G (passive) | Dec 31, 2025 |
| Vanguard Capital Management | 4,428,812 | 5.01% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KURA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,509,233 | 11.81% | $115.29M | +871,702 | 0.00% |
| Suvretta Capital Management, LLC | 8,575,422 | 9.64% | $94.07M | – | 1.72% |
| Bvf Inc/Il | 8,445,769 | 9.49% | $92.65M | – | 2.37% |
| State Street Corp | 5,329,208 | 5.99% | $58.46M | +817,317 | 0.00% |
| Vanguard Capital Management LLC | 3,916,164 | 4.40% | $42.96M | +130,479 | 0.00% |
| Armistice Capital, LLC | 3,678,000 | 4.13% | $40.35M | −58,000 | 0.49% |
| Aqr Capital Management LLC | 3,126,727 | 3.51% | $34.30M | +1,002,247 | 0.01% |
| Goldman Sachs Group Inc | 2,265,171 | 2.55% | $24.85M | +831,700 | 0.00% |
| Geode Capital Management, LLC | 2,229,958 | 2.51% | $24.47M | +195,682 | 0.00% |
| Alethea Capital Management, LLC | 2,167,938 | 2.44% | $23.78M | +638,569 | 9.85% |
| Prosight Management, LP | 2,021,964 | 2.27% | $22.18M | −1,334,736 | 3.82% |
| Deep Track Capital, LP | 1,978,565 | 2.22% | $21.70M | −664,977 | 0.32% |
| Renaissance Technologies LLC | 1,663,765 | 1.87% | $18.25M | +81,197 | 0.03% |
| Arrowstreet Capital, Limited Partnership | 1,410,275 | 1.59% | $15.47M | New | 0.01% |
| Vanguard Portfolio Management LLC | 1,329,941 | 1.49% | $14.59M | +99,139 | 0.00% |
| Nan Fung Trinity (Hk) Ltd | 1,174,880 | 1.32% | $12.89M | +110,000 | 1.27% |
| Qube Research & Technologies Ltd | 1,169,884 | 1.32% | $12.83M | −466,849 | 0.01% |
| Dimensional Fund Advisors LP | 1,169,189 | 1.31% | $12.83M | −256,756 | 0.00% |
| Bank Of America Corp /De/ | 1,160,921 | 1.30% | $12.74M | −69,210 | 0.00% |
| Morgan Stanley | 1,160,310 | 1.30% | $12.73M | −3,667 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 220 | 87M | 98.0% | 28 / 92 | 64 / 25 | 12M | 9M |
| Q1 2026 | 222 | 84M | 94.9% | 37 / 69 | 83 / 27 | 15M | 11M |
| Q4 2025 | 215 | 85M | 96.0% | 44 / 90 | 55 / 27 | 12M | 10M |
| Q3 2025 | 200 | 84M | 94.3% | 43 / 76 | 51 / 24 | 14M | 12M |
| Q2 2025 | 182 | 82M | 92.3% | 29 / 83 | 45 / 29 | 13M | 12M |
| Q1 2025 | 183 | 80M | 90.4% | 36 / 62 | 56 / 36 | 15M | 13M |
| Q4 2024 | 185 | 79M | 88.6% | 48 / 70 | 36 / 41 | 24M | 28M |
| Q3 2024 | 179 | 83M | 93.1% | 22 / 63 | 53 / 16 | 14M | 6M |
| Q2 2024 | 174 | 81M | 90.9% | 29 / 55 | 61 / 19 | 6M | 9M |
| Q1 2024 | 165 | 84M | 94.3% | 40 / 55 | 47 / 15 | 12M | 9M |
| Q4 2023 | 140 | 81M | 90.6% | 22 / 49 | 43 / 15 | 10M | 5M |
| Q3 2023 | 133 | 75M | 84.7% | 9 / 64 | 34 / 24 | 6M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
172 funds held KURA in Q2 2026, 68% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of KURA | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,105,747 | 3.49% | $34.07M | 0.32% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,799,338 | 3.15% | $30.71M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,210,614 | 2.48% | $24.25M | 0.03% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,026,943 | 1.15% | $11.27M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 928,988 | 1.04% | $8.37M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 785,096 | 0.88% | $8.61M | 0.06% | Jun 30, 2026 |
| iShares Biotechnology ETF | 606,113 | 0.68% | $6.65M | 0.07% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 564,979 | 0.64% | $5.76M | 0.11% | May 29, 2026 |
| Fidelity Extended Market Index Fund | 451,547 | 0.51% | $4.61M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 414,458 | 0.47% | $4.23M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 413,820 | 0.47% | $4.22M | 0.02% | May 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 300,321 | 0.34% | $3.29M | 0.11% | Jun 30, 2026 |
| U.S. Small Cap Portfolio | 268,920 | 0.30% | $2.42M | 0.01% | Jul 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 263,839 | 0.30% | $2.89M | 0.05% | Jun 30, 2026 |
| Vanguard Explorer Fund | 245,051 | 0.28% | $2.21M | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Troy Edward Wilson | President and CEO, Director | 1,414,650 | 1.59% | Nov 17, 2026 |
| Thomas James Doyle | SVP, Finance & Accounting | 138,581 | 0.16% | Nov 18, 2026 |
| Kathleen Ford | Chief Operating Officer | 132,276 | 0.15% | Nov 18, 2026 |
| Brian T. Powl | Chief Commercial Officer | 113,265 | 0.13% | Nov 18, 2026 |
| Teresa Brophy Bair | Chief Legal Officer | 178,401 | 0.20% | Nov 18, 2026 |
| Mollie Leoni | Chief Medical Officer | 99,845 | 0.11% | Nov 18, 2026 |
| Francis Burrows | Chief Scientific Officer | 63,053 | 0.07% | Sep 25, 2026 |
| Jennifer Fulk | Chief Financial Officer | – | – | Sep 10, 2026 |
| Helen Louise Collins | Director | – | – | Jun 4, 2026 |
| Diane L. Parks | Director | – | – | Jun 4, 2026 |
| Faheem Hasnain | Director | 23,983 | 0.03% | Jun 4, 2026 |
| Mary T. Szela | Director | – | – | Jun 4, 2026 |
| Thomas Malley | Director | 149,557 | 0.17% | Jun 4, 2026 |
| Michael Vasconcelles | Director | – | – | Jun 4, 2026 |
| Carol Schafer | Director | – | – | Jun 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mollie Leoni Chief Medical Officer | Nov 17, 2026 | Sale(10b5-1 plan) | −22,241 | $7.45 | $165.70K | 99,845 |
| Brian T. Powl Chief Commercial Officer | Nov 17, 2026 | Sale(10b5-1 plan) | −15,254 | $7.45 | $113.64K | 113,265 |
| Kathleen Ford Chief Operating Officer | Nov 17, 2026 | Sale(10b5-1 plan) | −3,668 | $7.46 | $27.36K | 132,276 |
| Thomas James Doyle SVP, Finance & Accounting | Nov 16, 2026 | Sale | −4,697 | $7.44 | $34.95K | 138,081 |
| Mollie Leoni Chief Medical Officer | Nov 16, 2026 | Sale(10b5-1 plan) | −19,009 | $7.44 | $141.43K | 122,086 |
| Brian T. Powl Chief Commercial Officer | Nov 16, 2026 | Sale(10b5-1 plan) | −9,196 | $7.44 | $68.42K | 127,623 |
| Teresa Brophy Bair Chief Legal Officer | Nov 16, 2026 | Sale(10b5-1 plan) | −8,601 | $7.44 | $63.99K | 178,401 |
| Kathleen Ford Chief Operating Officer | Nov 16, 2026 | Sale(10b5-1 plan) | −7,042 | $7.44 | $52.39K | 135,944 |
| Troy Edward Wilson President and CEO, Director | Nov 16, 2026 | Buy | +101,119 | $7.42 | $750.30K | 679,194 |
| Troy Edward Wilson President and CEO, Director | Nov 16, 2026 | Buy | +101,119 | $7.42 | $750.30K | 635,456 |
| Troy Edward Wilson President and CEO, Director | Nov 13, 2026 | Buy | +98,881 | $7.63 | $754.46K | 578,075 |
| Troy Edward Wilson President and CEO, Director | Nov 13, 2026 | Buy | +98,881 | $7.63 | $754.46K | 534,337 |
| Brian T. Powl Chief Commercial Officer | Sep 29, 2026 | Sale(10b5-1 plan) | −15,430 | $10.75 | $165.87K | 136,819 |
| Kathleen Ford Chief Operating Officer | Sep 29, 2026 | Sale(10b5-1 plan) | −3,668 | $10.75 | $39.43K | 142,986 |
| Mollie Leoni Chief Medical Officer | Sep 29, 2026 | Sale(10b5-1 plan) | −28,802 | $10.75 | $309.62K | 141,095 |
| Teresa Brophy Bair Chief Legal Officer | Sep 28, 2026 | Sale(10b5-1 plan) | −8,442 | $10.50 | $88.64K | 187,002 |
| Brian T. Powl Chief Commercial Officer | Sep 28, 2026 | Sale(10b5-1 plan) | −8,000 | $10.56 | $84.48K | 152,249 |
| Brian T. Powl Chief Commercial Officer | Sep 28, 2026 | Sale(10b5-1 plan) | −9,020 | $10.50 | $94.71K | 160,249 |
| Kathleen Ford Chief Operating Officer | Sep 28, 2026 | Sale(10b5-1 plan) | −6,906 | $10.50 | $72.51K | 146,654 |
| Thomas James Doyle SVP, Finance & Accounting | Sep 28, 2026 | Sale | −4,607 | $10.50 | $48.37K | 142,428 |
| Mollie Leoni Chief Medical Officer | Sep 28, 2026 | Sale(10b5-1 plan) | −12,448 | $10.50 | $130.70K | 169,897 |
| Francis Burrows Chief Scientific Officer | Sep 24, 2026 | Option exercise | +30,000 | $6.15 | $184.50K | 63,053 |
| Francis Burrows Chief Scientific Officer | Sep 24, 2026 | Sale | −20,726 | $10.83 | $224.46K | 42,327 |
| Troy Edward Wilson President and CEO, Director | Aug 24, 2026 | Buy | +100,000 | $12.39 | $1.24M | 479,194 |
| Brian T. Powl Chief Commercial Officer | Aug 21, 2026 | Sale(10b5-1 plan) | −4,345 | $11.89 | $51.66K | 169,269 |
| Teresa Brophy Bair Chief Legal Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −31,487 | $12.63 | $397.68K | 195,444 |
| Troy Edward Wilson President and CEO, Director | Aug 17, 2026 | Buy | +100,000 | $11.12 | $1.11M | 379,194 |
| Mollie Leoni Chief Medical Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −84,929 | $9.82 | $834.00K | 182,345 |
| Brian T. Powl Chief Commercial Officer | May 21, 2026 | Sale(10b5-1 plan) | −10,000 | $11.00 | $110.00K | 173,614 |
| Brian T. Powl Chief Commercial Officer | May 19, 2026 | Sale(10b5-1 plan) | −339 | $9.21 | $3.12K | 183,614 |
| Kathleen Ford Chief Operating Officer | May 19, 2026 | Sale(10b5-1 plan) | −2,257 | $9.08 | $20.49K | 153,560 |
| Teresa Brophy Bair Chief Legal Officer | May 18, 2026 | Sale(10b5-1 plan) | −2,256 | $9.38 | $21.16K | 226,931 |
| Troy Edward Wilson President and CEO, Director | Mar 23, 2026 | Option exercise | +6,103 | $6.15 | $37.53K | 435,456 |
| Thomas Malley Director | Mar 18, 2026 | Option exercise | +10,000 | $3.12 | $31.20K | 10,000 |
| Francis Burrows Chief Scientific Officer | Jan 27, 2026 | Sale | −1,311 | $8.46 | $11.09K | 32,424 |
| Kathleen Ford Chief Operating Officer | Jan 27, 2026 | Sale | −1,813 | $8.46 | $15.34K | 153,560 |
| Mollie Leoni Chief Medical Officer | Jan 27, 2026 | Sale | −2,233 | $8.46 | $18.89K | 269,566 |
| Mollie Leoni Chief Medical Officer | Jan 27, 2026 | Sale | −3,655 | $8.46 | $30.92K | 271,799 |
| Mollie Leoni Chief Medical Officer | Jan 27, 2026 | Sale | −951 | $8.46 | $8.05K | 268,615 |
| Mollie Leoni Chief Medical Officer | Jan 27, 2026 | Sale | −1,341 | $8.46 | $11.34K | 267,274 |
| Teresa Brophy Bair Chief Legal Officer | Jan 27, 2026 | Sale | −4,096 | $8.46 | $34.65K | 234,043 |
| Teresa Brophy Bair Chief Legal Officer | Jan 27, 2026 | Sale | −2,335 | $8.46 | $19.75K | 231,708 |
| Teresa Brophy Bair Chief Legal Officer | Jan 27, 2026 | Sale | −4,777 | $8.46 | $40.41K | 226,931 |
| Brian T. Powl Chief Commercial Officer | Jan 27, 2026 | Sale | −4,842 | $8.46 | $40.96K | 184,847 |
| Brian T. Powl Chief Commercial Officer | Jan 27, 2026 | Sale | −1,572 | $8.46 | $13.30K | 183,275 |
| Thomas James Doyle SVP, Finance & Accounting | Jan 27, 2026 | Sale | −2,226 | $8.46 | $18.83K | 150,083 |
| Thomas James Doyle SVP, Finance & Accounting | Jan 27, 2026 | Sale | −881 | $8.46 | $7.45K | 145,167 |
| Thomas James Doyle SVP, Finance & Accounting | Jan 27, 2026 | Sale | −2,226 | $8.46 | $18.83K | 146,048 |
| Thomas James Doyle SVP, Finance & Accounting | Jan 27, 2026 | Sale | −695 | $8.46 | $5.88K | 148,274 |
| Thomas James Doyle SVP, Finance & Accounting | Jan 27, 2026 | Sale | −1,114 | $8.46 | $9.42K | 148,969 |
| Teresa Brophy Bair Chief Legal Officer | Jan 2, 2026 | Award | +50,000 | – | – | 238,139 |
| Thomas James Doyle SVP, Finance & Accounting | Jan 2, 2026 | Award | +21,250 | – | – | 152,309 |
| Mollie Leoni Chief Medical Officer | Jan 2, 2026 | Award | +50,000 | – | – | 275,454 |
| Kathleen Ford Chief Operating Officer | Jan 2, 2026 | Award | +50,000 | – | – | 155,373 |
| Brian T. Powl Chief Commercial Officer | Jan 2, 2026 | Award | +50,000 | – | – | 189,689 |
| Francis Burrows Chief Scientific Officer | Dec 18, 2025 | Option exercise | +35,000 | $4.80 | $168.00K | 57,461 |
| Francis Burrows Chief Scientific Officer | Dec 18, 2025 | Sale | −23,726 | $9.78 | $232.04K | 33,735 |
| Faheem Hasnain Director | Dec 9, 2025 | Sale(10b5-1 plan) | −10,000 | $10.98 | $109.80K | 23,983 |
| Faheem Hasnain Director | Dec 9, 2025 | Option exercise | +10,000 | $3.12 | $31.20K | 33,983 |
| Mollie Leoni Chief Medical Officer | Nov 14, 2025 | Sale | −15,485 | $11.18 | $173.12K | 225,454 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Kura Oncology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,963 shares on Sep 17, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mollie Leoni Officer | Sep 29, 2026 | 28,802 | $305.59K | Sep 29, 2026 | Performance Stock Units |
| Brian T. Powl Officer | Sep 29, 2026 | 15,430 | $163.71K | Sep 29, 2026 | Restricted Stock Units |
| Kathleen Ford Officer | Sep 29, 2026 | 3,668 | $38.92K | Sep 29, 2026 | Performance Stock Units |
| Kathleen Ford Officer | Sep 28, 2026 | 6,906 | $74.31K | Sep 28, 2026 | PSU |
| Brian T. Powl Officer | Sep 28, 2026 | 9,020 | $97.06K | Sep 28, 2026 | RSU |
| Brian T. Powl Officer | Sep 28, 2026 | 8,000 | $86.08K | Sep 28, 2026 | Restricted Stock Units |
| Thomas James Doyle Officer | Sep 28, 2026 | 4,607 | $49.57K | Sep 28, 2026 | PSU |
| Teresa Brophy Bair Officer | Sep 28, 2026 | 8,442 | $90.84K | Sep 28, 2026 | PSU |
| Mollie Leoni Officer | Sep 28, 2026 | 12,448 | $133.94K | Sep 28, 2026 | PSU |
| Francis Burrows Officer | Sep 24, 2026 | 20,726 | $224.51K | Sep 24, 2026 | Stock Option Exercise |
| Brian T. Powl Officer | Aug 21, 2026 | 4,345 | $50.88K | Aug 21, 2026 | Restricted Stock Units |
| Teresa Brophy Bair Officer | Aug 19, 2026 | 31,487 | $388.23K | Aug 19, 2026 | Restricted Stock Units |
| Mollie Leoni Officer | Jun 18, 2026 | 84,929 | $812.77K | Jun 18, 2026 | Restricted Stock Units |
| Brian T. Powl Officer | May 21, 2026 | 10,000 | $103.40K | May 21, 2026 | Restricted Stock Units |
| Brian T. Powl Officer | May 19, 2026 | 339 | $3.12K | May 19, 2026 | Employee Stock Purchase Plan |
Congress trades
1 trade in Kura Oncology reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Christopher L. Jacobs NY27 | Bought | Dec 12, 2022 | $1K–15K | Jan 20, 2023 |
See a number that looks wrong?